(NASDAQ: CARM) Carisma Therapeutics's forecast annual revenue growth rate of 57.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Carisma Therapeutics's revenue in 2024 is $15,073,000.On average, 2 Wall Street analysts forecast CARM's revenue for 2024 to be $625,135,212, with the lowest CARM revenue forecast at $610,678,337, and the highest CARM revenue forecast at $639,633,629. On average, 1 Wall Street analysts forecast CARM's revenue for 2025 to be $631,449,709, with the lowest CARM revenue forecast at $631,449,709, and the highest CARM revenue forecast at $631,449,709.
In 2026, CARM is forecast to generate $2,824,906,592 in revenue, with the lowest revenue forecast at $2,824,906,592 and the highest revenue forecast at $2,824,906,592.